(MENAFN- America News Hour)
CRIFAX has recently added in its market research collateral archive, a report titled 'Japan NonSmall Cell Lung Cancer Market 2033-2033' . The market research report focuses on the emerging trends and the recent mergers and acquisitions amongst the major players in the industry. Further, the research report also covers a detailed analysis of the key growth strategies used by the leading market players to remain ahead of competition. Additionally, the report on Japan market also comprises of the challenges that may impact the market growth in the coming years along with a brief of the overall market environment that are associated with the market growth.
Get Exclusive Sample Report Copy Of This Report @
In Q4 2021, U.S. current-account deficit widened stood at $224.8 billion. However, in Q1 22, CAD rose by 29.6%, reached to $291.4 billion, adding $66.6 billion to the gap. Export of good and services increased by $25.7 billion to reach $1.03 trillion in the first quarter of 2022. However, country's goods and services deficit was $79.6 billion in June, down $5.3 billion from $84.9 billion in May, revised- reflecting some sight of relief. On the other hand, annual inflation rate in the country hit 8.5%. Energy CPI surged by 32.9% in July 2022, inflating the cost of logistic and signs to disrupt supply chain whilst electricity cost upsurged by 15.2%, highest since Feb 2006. Apart from that, In July 2022, existing US home sales declined 5.9% to 4.81 million (seasonally adjusted annual rate), the lowest since May of 2020 and below market expectations of 4.89 million. As mortgage rate touches highest at 6%, sales for houses declined for a sixth consecutive month. Global energy crises to remain at focal point impacting the economic activity in the U.S, pushing consumers to spend less on the products and services and save more.
On the other hand, the worst is expected to be seen in the European countries, especially during 2022 winters. The energy and gas crises has already started grappling the region, wherein many Western European countries including Germany is looking for coal fired solutions to tackle the gas supply shortage created by Russian-Ukraine conflict.
Amidst global concerns, market players have started looking for safe investments by holding on to the new technology and product launches. Factors like currency translation, disruption in global supply chain, Anti-China sentiments brewing across the globe, slowdown in Chinese economy, inflated products prices, USD getting stronger every week, decreasing purchasing power and strict measures taken by central banks/institutions across the world to ensure less spending and more saving, could hit the demand for the product and service badly in near future.
The Japan NonSmall Cell Lung Cancer Market is predicted to witness substantial expansion during the forecast period, i.e., 2023-2033 . The growth of the market can majorly be attributed to the growing geriatric population (aged 65 years or over) in the nation, which according to the statistical report titled World Population Ageing 2019 by the United Nations witnessed 35524 Thousands in the year 2019. This is further expected to reach 37278 Thousands by the end of 2030. Additionally, the percentage of individuals aged 65 years or over is expected to grow to 30.9% by the end of 2030, up from 28.0% in the year 2019. These growing geriatric population would be in need for advanced healthcare services, which is anticipated to drive the growth of market in the coming years.
On the other hand, the Japan NonSmall Cell Lung Cancer Market is also poised to grow on account of the numerous opportunities generated by the rising healthcare expenditure by the government of the nation. For instance, according to the statistics by the World Bank, the current health expenditure per capita in Japan grew from USD 2754.38 in the year 2006 to USD 4360.47 in the year 2019. As a share of GDP of the nation, the current health expenditure reached 10.74% in the year 2019, up from 7.69% in the year 2006. Further, the government health spending as a share of health spending in the nation touched 83.9% in the year 2019, up from 80.4% in the year 2000. Besides this, the out-of-pocket spending as a share of health spending reached 12.9% in the year 2019. Furthermore, amongst the sources of health expenditure, social health insurance contributions registered the largest share of 50.07% in the year 2019, followed by government transfers of 33.79%.
Click To Download Table of Contents Of This Report:
The Japan NonSmall Cell Lung Cancer Market research report provides an in-depth analysis of the market segmentation, and also provides other statistical figures, such as CAGR (Compound Annual Growth Rate) values, BPS review, Y-o-Y growth (percent), absolute $ potential, market's projected cost structure, and others. In addition to this, the market research report on market also further utilizes multi-dimensional analytical tools such as Porter's five-force model, SWOT and PESTEL to analyze the internal and external marketing factors associated with the market growth for the better understanding of its readers.
CRIFAX is driven by integrity and commitment to its clients and provides a step-by-step guide on achieving their business prospects with cutting-edge marketing research and consulting solutions. We make sure that our industry enthusiasts understand all the business aspects related to their projects with the help of our industry experts with hands-on experience in their respective fields, which further enhances the consumer base and the size of their organization. From customized and syndicated research reports to consulting services, we offer a wide range of unique marketing research solutions, out of which, we update our syndicated research reports annually to ensure that they are modified according to the latest and ever-changing technology and industry insights. This has enabled us to build a niche in offering 'distinctive market services' that strengthened the confidence in our insights of our global clients and helped us outperform our competitors as well.
U.K. Phone: +44 161 394 2021
U.S. Phone: +1 917 924 8284
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.